Catalyst Pharmaceuticals (CPRX) Enterprise Value (2010 - 2026)

Catalyst Pharmaceuticals has reported Enterprise Value for 17 years, with the latest figure at -$755.9 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 30.17% year-over-year to -$755.9 million; the trailing twelve-month figure through Mar 2026 stood at -$755.9 million (down 30.17% YoY), and the FY2025 full-year result was -$709.2 million, down 37.02% from the prior year.
• Enterprise Value for Q1 2026 stood at -$755.9 million, down from -$709.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$121.0 million in Q3 2023, with the low at -$755.9 million in Q1 2026.
• Historically, Enterprise Value has averaged -$387.8 million across 5 years, with a median of -$310.4 million in 2024.
• Annual changes were most pronounced in 2023 — Enterprise Value soared 53.87% — and 2024, when it sank 276.03%.
• Catalyst Pharmaceuticals' Enterprise Value stood at -$298.4 million in 2022, then soared by 53.87% to -$137.6 million in 2023, then slumped by 276.03% to -$517.6 million in 2024, then sank by 37.02% to -$709.2 million in 2025, then declined by 6.58% to -$755.9 million in 2026.
• The last three Enterprise Value figures came in at -$755.9 million (Q1 2026), -$709.2 million (Q4 2025), and -$689.9 million (Q3 2025), per Business Quant data.